NCT01833247

Brief Summary

This project looks at the time course of lactic acid rise (if any) after seizures. Salivary and capillary lactic acid are tested. This type of measurement may be useful in signalling the occurrence or recent history of a seizure.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2012

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

March 28, 2013

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 16, 2013

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
2.4 years until next milestone

Results Posted

Study results publicly available

May 5, 2017

Completed
Last Updated

May 5, 2017

Status Verified

May 1, 2017

Enrollment Period

2.4 years

First QC Date

March 28, 2013

Results QC Date

April 12, 2016

Last Update Submit

May 3, 2017

Conditions

Keywords

epilepsylactic acidsalivapostictal

Outcome Measures

Primary Outcomes (3)

  • Salivary Lactic Acid Levels With Seizures

    The investigators will assess the salivary lactic acid within 10 minutes after end of a seizure. Values will consist of lactic acid measurements in saliva , immediately post-seizure. Units of measurement will be mM/L. A positive outcome will be a curve different from a straight line, with a rise and fall of lactate levels. Baseline lactate serum level is expected to be less than 2.2 mM/L.

    Within 10 minutes of end of the seizure

  • Capillary Lactic Acid Levels With Seizures

    The investigators will assess the capillary lactic acid within 10 minutes after end of a seizure. Values will consist of lactic acid measurements in blood, within 10 minutes after the end of a seizure. Units of measurement will be mM/L. Baseline lactate serum level is expected to be less than 2.2 mM/L.

    Within 10 minutes of end of the seizure

  • Intravenous Lactic Acid Levels With Seizures

    The investigators will assess the intravenous lactic acid within 10 minutes after end of a seizure. Values will consist of lactic acid measurements in serum collected by IV, immediately post-seizure. Units of measurement will be mM/L. A positive outcome will be a curve different from a straight line, with a rise and fall of lactate levels. Baseline lactate serum level is expected to be less than 2.2 mM/L.

    Within 10 minutes of end of the seizure

Study Arms (1)

Epilepsy inpatients

Patients with epilepsy recorded in an inpatient video-EEG monitoring unit after a seizure.

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Age range will be 18-75, men and women, all ethnic backgrounds to be eligible. Eligible population will be determined by who gets admitted to the epilepsy monitoring unit with a history of generalized tonic-clonic seizures.

You may qualify if:

  • Age 18-75 inclusive.
  • History of at least one generalized tonic-clonic (grand mal) seizure prior to enrollment in the study.
  • Undergoing monitoring in the Stanford Epilepsy Monitoring Unit.

You may not qualify if:

  • Not pregnant.
  • Inability to understand and sign the consent form.
  • No known history of mitochondrial disease or other metabolic disorders expected to affect blood lactate.
  • No known peripheral vascular disease affecting blood circulation to the fingers.
  • No painful peripheral neuropathy.
  • No Raynaud's disease or phenomenon.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford Hospital

Stanford, California, 94305-5235, United States

Location

MeSH Terms

Conditions

Epilepsy

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Limitations and Caveats

Salivary lactic acid levels were difficult to reliably obtain with commercial devices designed to measure blood salivary levels. Because of low reliability, we did not pursue the study.

Results Point of Contact

Title
Robert S. Fisher, MD, PhD
Organization
Stanford University Department of Neurology

Study Officials

  • Robert S Fisher, MD, PhD

    Stanford University Department of Neurology

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Neurology

Study Record Dates

First Submitted

March 28, 2013

First Posted

April 16, 2013

Study Start

July 1, 2012

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

May 5, 2017

Results First Posted

May 5, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will share

If subjects wish to know their lactic acid levels after a seizure, we will provide the information, although it currently has no therapeutic or prognostic implications.

Locations